Cambridge, UK 22 May 2012

Isogenica today announces that it is appointing CTC Laboratory Systems Corporation (CTCLS) of Tokyo, Japan to represent the business in Japan.

CTCLS are a leading force in the pharmaceutical research market in Japan and their skilled and knowledgeable employees ensure that Isogenica’s innovative technology for antibody, protein and peptide design will find a new customer base in Japan.

Dr Kevin Matthews, CEO, Isogenica commented:

“The appointment of CTCLS is an important milestone for Isogenica and ensures that we can support our key customers in all the major world markets. We understand that direct personal contact, taking account of cultural and language differences, is fundamental to developing strong customer relationships. I am confident that CTCLS is the best organization to represent us and look forward to working with them to introduce Isogenica to the Japanese market as a whole as well as following-up on specific customer opportunities”.



Isogenica Ltd
Kevin Matthews, CEO, Isogenica
T: +44 (0)1799 533682
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

CTC Laboratory Systems Corporation, Japan
Hideki Negishi
T: +81 3-5712-8350
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Note to Editor:

About Isogenica

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies. Founded in 2000 Isogenica has developed a unique capability in the field of protein engineering. Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.

As a member of ITOCHU Techno-Solutions Corporation (CTC), CTCLS has evolved into one of Japan’s leading solution providers, specialising in the integration of R&D support systems for life science companies.

With incomparable end-to-end solution capability, CTCLS deals with pharmaceutical, chemical and food manufacturers, as well as universities and public offices, and offers a wide-range of products and services that cover every stage of R&D activities.